ClinicalTrials.gg
CompletedNCT06673667Updated Oct 2, 2025

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

A Phase 1 interventional study of KT-621 and Placebo in Healthy Participants Study, sponsored by Kymera Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Kymera Therapeutics, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

This is a first-in-human study to evaluate safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-621 in healthy male and female adult participants.

02

Conditions studied

  • Healthy Participants Study

Keywords

  • Phase 1
  • STAT6
  • STAT6 degrader
  • targeted protein degrader
03

In context

Lead sponsor

Kymera Therapeutics, Inc. is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 19 to 55 years (inclusive) at the time of consent, with a weight of at least 50 kg if male or 40 kg if female, and a (BMI) between 18.0 and 30.0 kg/m² (inclusive) at Screening.
  • Evidence of a personally signed and dated document indicating that the participant has been informed of all pertinent aspects of the study.
  • Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Male participants (and their partners of ) and female participants must agree to the requirements as specified in the clinical protocol.
  • Female participants may not be pregnant, lactating, or breast-feeding or plan to become pregnant (including ova donation) within 30 days of last study drug administration.
  • Female participants must have a negative result for pregnancy test at Screening and on admission to the CRU.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases or disorders.
  • Participants who have a clinically relevant surgical history (eg, surgery of the GI tract that could interfere with the PK of the trial medication) Note: prior appendectomy or cholecystectomy is not exclusionary.
  • Participants with a history of alcohol or substance abuse within the previous 5 years.
  • Participants who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
  • Participants who test positive for alcohol and drugs of abuse at Screening and on admission to the CRU.
  • Participants who have acute GI symptoms at the time of Screening or admission to the CRU (eg, nausea, vomiting, diarrhea, heartburn).
  • Participants whose results from clinical laboratory safety tests are outside the local reference range at Screening and on admission to the CRU.
  • Participants who have previously received KT-621 in another cohort in this study.
  • Participants who have been dosed with any drug or device in a clinical study within 30 days or 5 half-lives (whichever is longer) of KT-621/placebo administration.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
118 participants (actual)

Study arms

  • Active comparator
    KT-621

    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-621.

    Drug: KT-621

  • Placebo comparator
    Placebo

    Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.

    Drug: Placebo

Interventions

  • DrugKT-621

    Oral drug

  • DrugPlacebo

    Oral drug

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  2. Treatment-emergent potentially clinically-significant abnormalities in safety laboratory parameters: hematology

    Hemoglobin, Hematocrit, Erythrocytes, Mean corpuscular volume, Platelets, Leukocytes, Eosinophils, Basophils Neutrophils Lymphocytes Monocytes

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  3. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum chemistry

    Glucose, Blood urea nitrogen, Creatinine, Sodium, Potassium, Calcium, Chloride, Magnesium, Bicarbonate, Phosphate, Bilirubin, total and direct, Alkaline phosphatase, Aspartate transaminase (=SGOT), Alanine transaminase (=SGPT), Gamma glutamyl transferase, Total protein, Albumin, Creatine kinase, HbA1c, Lactate dehydrogenase (LDH)

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  4. Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulation

    Activated partial thromboplastin time, Prothrombin time, International Normalized Ratio, Fibrinogen

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  5. Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  6. Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  7. Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  8. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (breaths per minute)

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

  9. Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (degrees Celsius)

    Time frame: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)

Secondary outcomes

  1. Maximum concentration (Cmax): observed maximum concentrations derived from plasma concentration data

    Time frame: Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD)

  2. Time to maximum concentration (Tmax): observed time to achieve maximum concentrations derived from plasma concentration data

    Time frame: Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD)

  3. Area under the curve (AUC0-last): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to the last observed timepoint

    Time frame: Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD)

  4. Area under the curve (AUC0-infinity): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to infinite time

    Time frame: Day 1 (SAD)

  5. Area under the curve (AUC0-tau): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to end of the dosing interval

    Time frame: Day 1, Day 7, and Day 14 (MAD)

  6. Terminal elimination half-life (t1/2): elimination half-life calculated using non-compartmental analysis

    Time frame: Day 1 (SAD) and Day 14 (MAD)

  7. Fraction excreted: Fraction of drug excreted unchanged in urine

    Time frame: Day 14 (MAD)

Other outcomes

  1. Change from baseline in STAT6 protein levels in whole blood and peripheral blood mononuclear cells (SAD)

    Time frame: Day 1

  2. Change from baseline in STAT6 protein levels in whole blood, peripheral blood mononuclear cells, and skin (MAD)

    Time frame: Day 1 to Day 14

07

Study locations

2 sites
  • Celerion
    Phoenix, Arizona 85283, United States
  • Celerion
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Apr 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Nov 5, 2024
StartActual
Oct 22, 2024
Primary completionActual
Apr 23, 2025
CompletionActual
Apr 23, 2025
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06673667
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Oct 22, 2024
Primary completion
Apr 23, 2025
Completion
Apr 23, 2025
Last update
Oct 2, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KT-621

Start the discussion